1 TITLE (120 CHARACTERS MAX):

- 2 Investigating the relationship between IGF-I, -II and IGFBP-3 concentrations and later-life cognition
- 3 and brain volume
- 4 SHORT TITLE (50 CHARACTERS MAX): IIS, cognition and brain volume in the NSHD
- 5 AUTHORS:
- 6 Antoine Salzmann¹, Sarah-Naomi James¹, Dylan M. Williams^{1, 2}, Marcus Richards¹, Dorina Cadar³,
- 7 Jonathan M. Schott⁴, William Coath⁴, Carole H. Sudre^{4,5}, Nishi Chaturvedi¹ and Victoria Garfield¹

8 INSTITUTIONS:

- ⁹ ¹MRC Unit for Lifelong Health and Ageing at UCL, University College London, London, UK
- ²Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
- ³Department of Behavioural Science and Health, University College London, London, UK
- ⁴Department of Neurodegenerative Disease, The Dementia Research Centre, UCL Queen Square
- 13 Institute of Neurology, London, UK
- ⁵School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK

15 CORRESPONDING AUTHOR:

- 16 Antoine Salzmann
- 17 MRC Unit for Lifelong Health and Ageing at UCL
- 18 University College London
- 19 5th floor | 1-19 Torrington Place | London | WC1E 7HB | London, United Kingdom
- 20 Phone: +44 (0) 2076705723

21 Email: antoine.salzmann.14@ucl.ac.uk

- 22
- 23 TARGET JOURNAL: Journal of Clinical Endocrinology and Metabolism
- 24 **FUNDING:** This work was supported by the UK Medical Research Council, which provides core
- 25 funding for the MRC Unit For Lifelong Health and Ageing at UCL and the MRC National Survey of
- Health and Development (MC_UU_00019/1) and supports AS, NC, DW, MR, SNJ (MC_ST_LHA_2019;
- 27 MC_UU_0019/2, MC_UU_0019/3). Insight 46 is principally funded by grants from Alzheimer's
- 28 Research UK (and SNJ ARUK-PG2014-1946, ARUK-PG2017-1946), the Medical Research Council
- 29 Dementias Platform UK (CSUB19166), the Wolfson Foundation (PR/ylr/18575) and The Drake

30 Foundation. JMS acknowledges the EPSRC (EP/J020990/1) and European Union's Horizon 2020

- 31 research and innovation programme (Grant 666992) and a Weston Brain Institute and Selfridges
- 32 Group Foundation award (176724). DC is funded by the National Institute on Aging (RO1AG017644)
- and ESRC (ES/S013830/1). CHS is supported by an Alzheimer's Society Junior Fellowship (AS-JF-17-
- 34 011). VG is funded by Joint Diabetes UK and British Heart Foundation (15/0005250).
- 35 DISCLOSURE: JMS has received research funding from Avid Radiopharmaceuticals (a wholly owned
- 36 subsidiary of Eli Lilly), has consulted for Roche Pharmaceuticals, Biogen, and Eli Lilly, given
- 37 educational lectures sponsored by GE, Eli Lilly and Biogen, and serves on a Data Safety Monitoring
- 38 Committee for Axon Neuroscience SE. NC receives funds for serving on a Data Safety Monitoring
- Committee for a study sponsored by AstraZeneca. All other authors have no conflicts of interest todeclare.
- 41 KEYWORDS (6 max): IGF-1, IGF-2, Cognition, Ageing, Epidemiology, Brain volume

43 Abstract (250 words max)

44 Background: The insulin/insulin-like signalling (IIS) pathways, including Insulin-like Growth Factors

- 45 (IGFs), varies with age. However, their association with late-life cognition and neuroimaging
- 46 parameters is not well characterised.
- 47 Methods: Using data from the British 1946 birth cohort we investigated associations of IGF-I, -II and
- 48 IGFBP-3 (measured at 53 and 60-64 years) with cognitive performance (word learning test (WLT)
- 49 and visual letter search (VLS) at 60-64y and 69y) and cognitive state (Addenbrooke's Cognitive
- 50 Exam-III (ACE-III) at 69-71y), and in a proportion, quantified neuroimaging measures (whole brain
- 51 volume (WBV); white matter hyperintensity volume (WMHV); hippocampal volume (HV)).
- 52 Regression models included adjustments for demographic, lifestyle and health factors.
- 53 **Results:** Higher IGF-I and IGF-II at 53y was associated with higher ACE-III scores (ß 0.07 95%CI
- 54 [0.02,0.12]; score_{ACE-III} 89.48 [88.86,90.1], respectively). IGF-II at age 53y was additionally associated
- with higher WLT scores (score_{WLT} 20 [19.35,20.65]). IGFBP-3 at 60-64y was associated with
- 56 favourable VLS score at 60-64y and 69y (ß 0.07 [0.01,0.12]; ß 0.07 [0.02,0.12], respectively), higher
- 57 memory and cognitive state at 69y (ß 0.07 [0.01,0.12]; ß 0.07 [0.01,0.13], respectively) and reduced
- 58 WMHV (ß -0.1, [-0.21,-0.00]). IGF-I/IGFBP-3 at 60-64y was associated with slower VLS scores at 69y
- 59 (ß -0.08, [-0.15,-0.02]).
- Conclusions: Increased measure in IIS parameters (IGF-I, -II and IGFBP-3) relate to better cognitive
 state in later life. Furthermore, there were apparent associations with specific cognitive domains
 (IGF-II relating to memory; IGFBP-3 to memory, processing speed and WMHV; and IGF-I/IGFBP-3
 molar ratio with slower processing speed). IGFs and IGFBP-3 are associated with favourable cognitive
 function outcomes.

65 Word count: 250 words

66 Introduction

67	The Growth Hormone/Insulin-like Growth Factor signalling pathway is thought to play a key
68	role in ageing health and the determination of age-related diseases. In humans, this pathway is
69	regulated through the somatotropic axis, which consists mainly of growth hormone (GH), Insulin-like
70	Growth Factors (IGF) and their respective binding proteins (1). IGF-I binds to IGF binding proteins
71	(IGFBP) in high-affinity complexes to prevent degradation and binding to the IGF-I receptor (IGF1R),
72	thus leaving concentrations of 'free' circulating IGF-I relatively low. As such, the ratio of IGF-I to
73	binding proteins provides an indication of bioavailability (1–3), whilst also mediating its effect via
74	IGF1R; IGF-II bioavailability is also regulated by the IGF2 receptor (4). IGFBP-3, however, has also
75	been shown to have IGF-independent associations on phenotypes(5).
76	Whereas research supports an important role of Insulin/Insulin-like Signalling (IIS) in
77	early brain development and neuroplasticity, as evidenced by developmental defects associated
78	with mutations in the IGF1R gene, its role in the maintenance of brain function is less well
79	understood (6,7). Observational studies are conflicting, with some reporting protective, detrimental,
80	'U' shape and null associations (8,9). The relationship between IGF-II and cognition and neurological
81	health, on the other hand, remains largely uncharacterised, with only one study to date, which
82	reported raised IGF-II concentrations in association with better cognition, while no association of
83	IGF-I was observed (10)
84	The MRC National Survey for Health and Development (NSHD; also known as the 1946
85	British Birth Cohort), provides an ideal opportunity to study the relationship between measures of
86	the IIS axis through mid-life, and cognition and brain volume in later life (11). IGF-I and -II collection
87	at multiple time points may help resolve previous discrepant findings by considering differential
88	associations of age, and duration of follow-up. Additionally the NSHD has a wealth of data across the
89	life-course, allowing us to control for potential confounders which have been omitted or based on

90	recalled data in	past studies, such as ear	lv-life cognition an	d historical affective s	vmptoms.	Finally.
	recuired data in	pase sea ares, saon as car		a motorroar arrestive s	,	

- 91 neuroimaging data enables associations with brain volume and neurovascular health to be studied in
- 92 tandem with cognitive function.
- 93 We aimed to examine associations of IGF-I, IGFBP-3, and IGF-II measured at ages 53 and 60-
- 94 64 with cognitive function at ages 60-64 and 69, and volumetric and cerebrovascular neuroimaging
- 95 parameters (total brain, hippocampal and white matter hyperintensity volumes) at age 69-71.

96

97

99 Methods

100 Study participants

101	The NSHD recruited 5,362 participants born within one week in March 1946 in England,
102	Scotland and Wales. The cohort has remained in continuous follow-up from birth to date, with 24
103	sweeps of investigation (12). Cognitive function at age 69 was our primary outcome. At this age,
104	2149 participants were interviewed. Loss to follow-up was due to death (19.1%), refusal (20.6%),
105	emigration or being temporarily abroad (10.8%) or because the participant could not be contacted
106	or traced (7.8%). Figure 1 outlines the number of participants with information concerning exposure
107	and outcome variables and the final sample (n=1762) used for analysis.
108	We additionally examined associations with neuroimaging outcomes in a sub-sample who
109	had participated in the neuroimaging sub-study, Insight 46(13). Details have previously been
110	published (13), but in brief this study included 502 individuals who underwent positron emission
111	tomography-magnetic resonance imaging (PET-MRI) scanning using a single Biograph mMR 3T PET-
112	MRI scanner (Siemens Healthcare, Erlangen), with simultaneous acquisition of PET/MRI data,
113	including volumetric (1.1 mm isotropic) T1 and fluid-attenuated inversion recovery (FLAIR)
114	sequences(13). Volumetric T1-weighted and FLAIR images underwent visual quality control prior to
115	processing following an automated pipeline(13). Relevant imaging measures were isolated as
116	follows: total brain volume (TBV) using Multi-Atlas Propagation and Segmentation(14), mean
117	hippocampal volume (HV) using Similarity and Truth Estimation for Propagated Segmentations(15),
118	total intracranial volume (TIV) using SPM12 (Wellcome Centre for Human Neuroimaging) and white
119	matter hyperintensity volume (WMHV) using Bayesian model selection (BaMoS)(16,17). WMHV was
120	isolated from 3D T1 and FLAIR images followed by visual inspection to generate a global WMHV,
121	including subcortical gray matter but excluding infratentorial regions(17,18). Eligibility criteria, the
122	study protocol, and a comparison of those who did and who did not participate in Insight 46 have

123	been described in detail elsewhere	(13.1	L8)	. Of the 502 Insi	ght 46	participant	s. com	plete

- 124 neuroimaging and ACE-III data were available for 378.
- 125 Measures
- 126 IGF-I, IGF-II and IGFBP-3 measurements
- 127

128	Blood samples were collected at age 53 (non-fasting), and age 60-64 (fasting). IGF-I, IGF-II
129	and IGFBP-3 concentrations were obtained by radioimmunoassay using standard protocols in the
130	same laboratory. The intra-assay coefficient of variation (CV) for IGF-I, IGF-II and IGFBP-3 were 3.4%,
131	2.8% and 3.9%, respectively. The inter-assay CV was 13.7%, 7.4% and 11.7% for IGF-I, IGF-II and
132	IGFBP-3, respectively (19). IGF-I, IGF-II and IGFBP-3 values were converted from ng/ml to standard SI
133	units: nmol/L (20,21). IGF-I/IGFBP-3 values were calculated as molar ratios as an indicator of IGF-I
134	bioavailability.

135

136 Cognitive performance measures

137

138	Three separate tests were used to measure cognitive domains. At 60-64 and 69,
139	standardised versions of a Word Learning Test (WLT) and Visual Letter Search test (VLS) were used
140	to assess memory and processing speed, respectively. The WLT consists of a 15-word learning task
141	devised for the NSHD. Each word was shown to the participant for 2 seconds and partcipants were
142	asked to immediately write down as many words as they could remember. The task was repeated
143	three times, and the scores were summed (max = 45), which is representative of short-term episodic
144	memory (22,23). The VLS required participants to scan for the letters 'P' and 'W' among other letters
145	and cross out as many of these letters within one minute. Search speed score was based on how far
146	the participant got in the grid search, with a maximum score of 600 signifying they had completed
147	the whole grid (22).

148	The Addenbrooke's Cognitive Examination-III (ACE-III) is a test for cognitive state
149	administered at age 69 (24,25). The test assesses five domains, each with different score ranges:
150	Attention (0-18), memory (0-26), Fluency (0-14), Language (0-26) and Visuospatial (0-16). The test
151	was administered either online using an iPad (<u>http://www.acemobile.org/</u>) or by paper if the former
152	was not possible. Paper tests were scored by trained personnel (24,26). Unlike most tests of
153	cognitive state, the ACE-III total score (max = 100) has a quasi-normal distribution, making it
154	appropriate for parametric statistical analyses.
155 156	Covariates

157 Covariates were selected a priori, based on previous studies and added into our models 158 successively. Model 1 had sex, Model 2 included additional adjustments for childhood cognition and 159 educational attainment, Model 3 added smoking status at the time of exposure and Model 4 added 160 affective symptoms at the time of outcome (10,27,28). The same models were used when 161 investigating the relationship between exposures and brain volume with TIV additionally controlled 162 for in all volumetric outcome models. 163 Childhood cognition at age 8 was assessed by four tests administered by trained observers: 164 reading comprehension, word pronunciation, vocabulary and non-verbal reasoning. Total scores 165 were standardised to the study population. Lifetime education attainment was based on the highest 166 educational qualification by the age of 43 years (26) and categorised as 1) no qualification or 167 vocational gualifications 2) ordinary, advanced secondary and 3) tertiary gualifications. Smoking 168 status was obtained from questionnaires and classified into current smoker, ex-smoker and never 169 smoker at age 53 and 60-64 (29). Affective symptoms were self-reported at ages 60-64 and 69 years 170 using the 28-item General Health Questionnaire (GHQ-28) (30). A threshold, set at the 171 recommended 4 (non case) / 5 (case) cut was imposed on the GHQ-28 total score to determine case-172 level symptoms (30,31).

173 Statistical analyses

174	WMHV was \log_{e} -transformed to account for skewness. ANOVA tests were used to examine
175	exposure and outcome variable differences at different timepoints. Within the selected sample,
176	missing data ranged from 0.1% to 27.9% for affective case symptoms (age 69) and IGF-I/IGFBP-3
177	molar ratio (age 60-64) respectively. To minimise data loss, missing data for exposure, WLT, VLS and
178	covariate variables were imputed using multiple imputation by chained equations (MICE).
179	Imputation models included all model variables, except for volumetric outcomes. Datasets were
180	imputed 20 times using a Bayesian linear regression model(32).
181	Linear regression models were used to assess the relationship between exposure and
182	outcomes. Results are presented as standardised beta values with 95% confidence intervals. To
183	determine whether the associations of IGFs and IGFBP-3 with cognition and brain volume differed by
184	sex, which may warrant stratification, an interaction term for sex was tested at the 10% significance
185	level for all exposures. No interaction was found between sex and exposure variables, so main
186	models were not stratified by sex. In addition, a quadratic term for the exposure was tested to
187	explore the possibility of non-linear associations. A quadratic relationship was observed between
188	IGF-II and general cognitive state and visual memory. Therefore, for associations with cognitive
189	function, IGF-II measurements were categorised into tertiles.
190	All statistical analyses were performed in R version 3.5.2(33). Multiple imputation was
191	performed using the 'mice' package in R(32). Relevant R script is available upon request.
192	
193	Results

194 Sample characteristics

195Of the 1762 NSHD participants with cognitive state measured at age 69, 849 (48%) were196male, and 913 (52%) were female. The Insight 46 imaging sub-study at age 69-71 (mean age: 70.67

197 years, SD: 0.67) included 378 of these 1762 NSHD participants. Of these, 194 (51%) were male and
184 (49%) female (Table 1).

199	In the entire cohort at age 60-64, pattern shows that IGF-I concentrations were lower, and
200	IGFBP3 levels substantially lower than at age 53 (Table 1). As a result, bioavailable IGF (IGF1/IGFBP3
201	ratio) was higher at age 60-64 than 53. IGF-II concentrations were lower at age 60-64 than age 53.
202	Visual memory (WLT) and processing speed (VLS) were lower with increasing age at investigation, as
203	previously described (Table 1)(34).

204 IGF-I

205 Higher IGF-I measures at age 53 and 60-64 were associated with better cognitive function

206 for the WLT and ACE-III cognitive measures, but not for the VLS (Figure 2). These associations

reached conventional levels of statistical significance for IGF-I at age 53 and ACE-III at age 69 (ß 0.07,

208 95% CI 0.02,0.12, p = 0.008). Adjustment for childhood cognition and educational attainment

attenuated this estimate to ß 0.04, 95% CI 0.00,0.09, p = 0.063. Further adjustment for smoking

status and emotional symptoms did not alter the estimate (Figure 2).

In the subjects with imaging available, higher concentrations of IGF-I at age 60-64 were directionally associated with a 8% lower WMHV at age 71 years (95% CI -19%, 3%, p = 0.142), yet did not reach conventional levels of significance. Adjustment for the covariates did not affect this trend (Figure 4).

215 Bioavailable IGF-I

216

Bioavailable IGF-I was associated with lower VLS and ACE-III scores (Figure 2). Elevated IGF-I/IGFBP-3 concentrations at age 60-64 were associated with slower VLS at age 69 (ß -0.08, 95% CI -0.15,-0.02, p = 0.019) (Figure 2). In contrast to IGF-I models, adjustment for childhood cognition and education did not attenuate effect sizes. No clear associations with brain volume were observed (Figure 4).

222 IGFBP-3

223	Higher concentrations of IGFBP-3 at age 60-64 were associated with faster processing speed
224	at age 60-64 and 69 (ß 0.07, 95% Cl 0.01,0.12, p = 0.014 and ß 0.07, 95% Cl 0.02,0.12, p = 0.012,
225	respectively) (Figure 2). The addition of covariates did not affect this association (Figure 2). Higher
226	concentrations of IGFBP-3 at age 60-64 were additionally associated with higher scores for memory
227	and cognitive state at age 69 (ß 0.07, 95% Cl 0.01,0.12, p = 0.017 and ß 0.07, 95% Cl 0.01,0.13, p =
228	0.033, respectively) (Figure 2). Adjustment for education and childhood cognition attenuated these
229	estimates to ß 0.05, 95% CI 0:00,0.10, p = 0.034 and ß 0.05, 95% CI 0:00,0.10, p = 0.07, respectively
230	(Figure 2).
231	Higher concentrations of IGFBP-3 at age 60-64 were additionally associated with a 10%
232	lower WMHV at age 71 years (ß -0.1, 95% Cl -0.21,0.00, p = 0.059). Adjustment for the covariates did

233 not affect this association.

234 IGF-II

Similarly to IGF-I, higher concentrations of IGF-II were associated with better cognitive function for the WLT and ACE-III cognitive measures, but not with VLS (Figure 3). At age 53, the lowest tertile of circulating IGF-II concentration was associated with a lower ACE-III score at age 69 (score_{ACE-III} 89.48, 95% CI 88.86,90.1, p = 0.022, tertile 1) (Figure 3). Similarly, lowest tertiles of IGF-II at age 53 were associated with lower memory at age 69 (score_{WLT} 20, 95% CI 19.35,20.65, p = 0.085, tertile 1). As for bioavailable IGF-I, no associations with brain volume were observed (Figure 4).

241

243 Discussion

244	In this UK population sample, IGF-I and –II concentrations at age 53, and IGF-I
245	concentrations at age 60-64, were positively associated with cognitive state at age 69, assessed by
246	the Addenbrooke's Cognitive Examination (ACE-III) and verbal memory, but not with processing
247	speed. Higher IGFBP-3 concentrations at age 60-64 were associated with overall higher cognition.
248	Adjustment for childhood cognition and educational attainment attenuated associations, but did not
249	wholly account for them. In addition, IGF-I and IGFBP-3 at age 60-64 were associated with lower
250	white matter hyperintensity burden at age 69-71. Multivariable adjustment did not notably alter
251	these associations. Surprisingly, there was a trend towards worse cognitive state and processing
252	speed in those with higher IGF-I/IGFBP-3 ratio levels.
253	The positive relationship between IGF-I and general cognitive state reflects findings in the
254	Nurses Health Cohort (NHC), which found an association between IGF-I and verbal memory
255	attenuated after adjustment for educational attainment (35). NHC participants were of similar age to
256	NSHD participants at our 2 nd baseline (60-64) years, and main follow-up point (69 years). Additionally
257	though, we suggest associations are similar in men and women, and show that cognitive
258	performance is related to IGF-I sampled earlier in life, at age 53. Our findings conflict with
259	observation of a an adverse(36), or 'U' shaped relation(37), of IGF-I on cognition. The former
260	analyses were performed cross-sectionally in much older participants (≥95 years), while the latter
261	spanned ages 48-88 at follow-up. Age dependent pleiotropic effects of IGF-I could potentially
262	account these conflicting findings; specifically, if IGF-I acts beneficially in middle age and early older
263	age, but has adverse effects in late older age. A 'U' shaped association may therefore be observed if
264	participants span early and late older age.
265	IGF-I plays an essential role in brain development and homeostasis, including
266	neurogenesis, neuronal differentiation and angiogenesis (8,38). Prospective analyses of the
267	Framingham Heart Study found that higher concentrations of IGF-I were associated with larger brain

268	volumes in healthy participants, potentially suggestive of some protection against
269	neurodegeneration (39). Association magnitudes were doubled in the parent versus the offspring
270	cohort (mean ages 79 years and 61 years, respectively), again highlighting an important age
271	dependency. Whilst we did not observe an association between IGF-I and TBV, IGF-I was associated
272	with lower WMHV, an indicator of cerebral small vessel damage. To our knowledge, no previous
273	study has explored the association between IGF-I and cerebral small vessel disease. A 10-year
274	prospective study found stroke incidence to be associated with lower circulating IGF-I
275	concentrations (40). Other studies have shown improved outcomes following ischemic stroke in
276	participants with higher IGF-I concentrations (41). In hypertensive mice, liver-specific IGF-I-
277	knockdown treatment was associated with increased and earlier incidence of cerebral
278	microhaemorrhages, as compared to control mice, likely due to impaired remodelling processes(42).
279	Mechanisms underlying protective effects of IGF-I on the vasculature include anti-inflammatory
280	properties, preservation of endothelial function, and a positive association with cardiovascular risk
281	factors such as obesity and insulin resistance (40). Whilst our findings did not reach conventional
282	levels of statistical significance, effect sizes, consistency with previous research, and strong biological
283	plausibility supports further investigation.
284	Surprisingly, however, associations with bioavailable IGF-I (i.e. IGF-I/IGFBP-3 ratio) were

Surprisingly, however, associations with bioavailable IGF-I (i.e. IGF-I/IGFBP-3 ratio) were 284 285 opposite to those observed for IGF-I alone, with the ratio associated with reduced processing speed 286 and, to a lesser degree, cognitive state. This can be explained by IGFBP-3 being positively associated 287 with cognition independently of IGF-I, and that the age-related decline in IGFBP-3 was markedly 288 greater than that for IGF-I. IGFBPs have been shown to execute IGF-I independent actions, including 289 mediation of cell proliferation, apoptosis and survival (43,44). We observed globally improved 290 cognitive outcomes associated with increased circulating IGFBP-3 concentrations. In line with our 291 results, higher concentrations of IGFBP-3 were found to be cross-sectionally associated with better 292 cognitive state in women in the Mayo Clinic Study of Ageing and reduced dementia incidence in 293 men(45,46). In mice, null mutations in the Igfbp3 gene resulted in impaired neuronal structure and

signalling and spatial working memory (47). However, findings are not consistent across studies with
higher concentrations of IGFBP-3 related to poorer cognition in males in the Caerphilly Prospective
Study (CaPS) (10). Our findings highlight the importance of exploring associations with individual
factors that form a biologically meaningful molecular ratios, and understanding age-related changes
in exposures, which, as we show, may not be equivalent across associated measures.

In addition to favourable cognitive outcomes, IGFBP-3 was conjointly associated with a 10%
reduction in WMHV in our study. Several studies have implied the possibility of a beneficial
association between IGFBP-3 and cerebral small vessel disease. High concentrations of circulating
IGFBP-3 are associated with reduced risk of ischaemic stoke and improved functional outcomes
following stroke events(41,48,49). In mice, IGFBP-3 was shown to protect retinal vasculature from
hyperoxia-induced vessel regression and, *in vitro*, promoted differentiation of endothelial precursor
cells to endothelial cells, indicating a potential pathway by which IGFBP-3 may reduce WMHV (5,50).

306 Few studies have examined the relationship between IGF-II and cognitive outcomes. IGF-II 307 has traditionally been seen as relatively unimportant beyond fetal development. However, there is 308 increasing evidence relating detrimental IGF-II expression to disease after birth (4,51). To our 309 knowledge, only one other study has investigated the role of IGF-II on later-life cognition. The CaPS 310 found a reduced occurrence of cognitive impairment without dementia with higher circulating IGF-II 311 concentrations, but not with cognitive state. In addition, they did not find an association between 312 IGF-I and cognitive function (10). In our study, we found a time-dependent association between 313 higher IGF-II at age 53 and better visual memory and cognitive state at age 69, presenting similarities 314 to the results obtained from the IGF-I models. This suggests a common pathway, likely via signalling 315 downstream of the IGF-1R. Discrepancies between our findings and those from the CaPS may be 316 driven by choice of outcome. The CaPS studied CIND, dementia and 'normal' cognitive ageing 317 separately, therefore excluding participants with CIND or dementia from models studying 'normal' 318 cognitive ageing. It is possible that 'normal' and 'abnormal' cognitive ageing are driven by separate

319 mechanisms and IGF-I and IGF-II might be protective in the context of 'abnormal' cognitive ageing320 only.

321 Our study has some important strengths, including a prospective design with long follow-up 322 (16 years) and important confounders, including childhood cognition. To our knowledge, it is the 323 only study to use repeat exposure and outcome measures to better understand the temporal 324 relationship between IGFs and cognition. Age-dependent relationships may reflect separate 325 underlying biological pathways acting at different points in the life course. In addition, it is the first 326 study to investigate both cognitive function and structural brain measures. However, it is important 327 to consider some limitations of the present study. To investigate bioavailable IGF-I, this study used 328 the ratio of IGF-I to IGFBP-3. However, binding proteins have been shown to have IGF-I independent 329 actions (43). Conflicting results between IGF-I and bioavailable IGF-I in our study were seemingly 330 explained by IGF-I-independent associations between IGFBP-3 and cognition, thereby supporting 331 future study of IGFBP-3 independently from IGF-I. However, the use of 'free' IGF-I may provide a 332 more accurate view of the role of unbound circulating IGF-I on brain health(52). Finally, with the 333 latest follow-up at age 69, participants are still not old enough for severe cognitive decline to be 334 common, which may have limited statistical power to detect moderate to small associations.

335 In light of these findings, we would suggest further studies to determine the exact domains 336 which may be affected by IGF-I, -II and IGFBP-3 concentrations. This could be done by using an array 337 of cognitive tests that probe distinct cognitive domains. Further studies continuing to use repeat IGF 338 and IGFBP exposure and cognition measures across the life course may help provide a better 339 understanding of the complex relationship between the two. Reexamination of the relationships in 340 the NSHD at an older age would be essential to understand age-dependent effects and potentially 341 address the current inconsistencies in the field. Furthermore, genetic approaches to study the 342 association between polygenic risk scores and cognition across the age spectrum may provide an 343 alternate method to investigate relationships across the life course.

344	While repeat measures in our study have highlighted the importance of time of exposure,
345	outcome and follow-up period, further work is required to disentangle the temporal nature of the
346	IIS-brain health relationship. Regular IGF-I, -II, IGFBP-3 and cognition measures throughout the life
347	course would help to elucidate this. As autocrine and paracrine IGF-I concentrations vary with age,
348	narrowing the age range at each sample collection could also prove essential(53,54). The wide age
349	range in a number of studies may prove responsible for some of the heterogeneity currently
350	observed in results (37,52,55).
351	In conclusion, in this UK birth cohort, higher circulating IGF-I and -II levels were prospectively
352	associated with favourable cognitive state, whilest IGF-I/IGFBP-3 ratio was associated with slower
353	processing speed. IGF-II was additionally associated with better memory performance. IGFBP-3 was
354	indepependently associated with cognitive state, memory, processing speed and WMHV. The
355	present study has not only added to our understanding of the IIS-cognition relationship, but
356	crucially, it has elucidated the importance of using a breadth of neuroimaging, cognitive function

and state to understand more holistically how IGFs and IGFBPs relate to brain health from mid to
later life.

359

360 Acknowledgments

361 The authors are grateful for the continued support of the NSHD study members without whom this

- 362 study would not have been possible. We would also like to acknowledge Dr. Andy Wong for
- assistance in data extraction and management, and the Insight 46 study team.

364

365 Data availability:

366 Access to relevant data available upon application to the NSHD data sharing committee.

367 References

- Milman S, Huffman DM, Barzilai N. The somatotropic axis in human aging: Framework for the current state of knowledge and future research. *Cell Metab.* 2016;23(6):980-989.
 doi:10.1016/j.cmet.2016.05.014
- Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic
 bioactivities. *Am J Physiol Endocrinol Metab.* 2000;278(6):E967-976.
 doi:10.1152/ajpendo.2000.278.6.E967
- Juul A, Main K, Blum WF, Lindholm J, Ranke MB, Skakkebaek NE. The ratio between serum
 levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3)
 decreases with age in healthy adults and is increased in acromegalic patients. *Clin Endocrinol* (*Oxf*). 1994;41(1):85-93. doi:10.1111/j.1365-2265.1994.tb03788.x
- Chao W, D'Amore PA. IGF2: Epigenetic regulation and role in development and disease.
 Cytokine Growth Factor Rev. 2008;19(2):111-120. doi:10.1016/j.cytogfr.2008.01.005
- 3815.Jogie-Brahim S, Feldman D, Oh Y. Unraveling Insulin-Like Growth Factor Binding Protein-3382Actions in Human Disease. Endocr Rev. 2009;30(5):417-437. doi:10.1210/er.2008-0028
- Byer AH, Vahdatpour C, Sanfeliu A, Tropea D. The role of Insulin-Like Growth Factor 1 (IGF-1) in
 brain development, maturation and neuroplasticity. *Neuroscience*. 2016;325:89-99.
 doi:10.1016/j.neuroscience.2016.03.056
- Abuzzahab MJ, Schneider A, Goddard A, et al. IGF-I Receptor Mutations Resulting in
 Intrauterine and Postnatal Growth Retardation. *N Engl J Med*. 2003;349(23):2211-2222.
 doi:10.1056/NEJMoa010107
- Frater J, Lie D, Bartlett P, McGrath JJ. Insulin-like Growth Factor 1 (IGF-1) as a marker of cognitive decline in normal ageing: A review. *Ageing Res Rev.* 2018;42:14-27.
 doi:10.1016/j.arr.2017.12.002
- Gubbi S, Quipildor GF, Barzilai N, Huffman DM, Milman S. 40 YEARS of IGF1: IGF1: the Jekyll
 and Hyde of the aging brain. J Mol Endocrinol. 2018;61(1):T171-T185. doi:10.1530/JME-18 0093
- Green CJ, Holly JMP, Bayer A, et al. The role of IGF-I, IGF-II, and IGFBP-3 in male cognitive aging
 and dementia risk: the Caerphilly Prospective Study. J Alzheimers Dis JAD. 2014;41(3):867-875.
 doi:10.3233/JAD-132183
- Kuh D, Wong A, Shah I, et al. The MRC National Survey of Health and Development reaches age
 70: maintaining participation at older ages in a birth cohort study. *Eur J Epidemiol*.
 2016;31(11):1135-1147. doi:10.1007/s10654-016-0217-8
- 401 12. Wadsworth M, Kuh D, Richards M, Hardy R. Cohort Profile: The 1946 National Birth Cohort
 402 (MRC National Survey of Health and Development). Int J Epidemiol. 2006;35(1):49-54.
 403 doi:10.1093/ije/dyi201

404 405 406	13.	Lane CA, Parker TD, Cash DM, et al. Study protocol: Insight 46 – a neuroscience sub-study of the MRC National Survey of Health and Development. <i>BMC Neurol</i> . 2017;17(1):75. doi:10.1186/s12883-017-0846-x
407 408 409	14.	Leung KK, Barnes J, Modat M, et al. Brain MAPS: An automated, accurate and robust brain extraction technique using a template library. <i>NeuroImage</i> . 2011;55(3):1091-1108. doi:10.1016/j.neuroimage.2010.12.067
410 411 412	15.	Jorge Cardoso M, Leung K, Modat M, et al. STEPS: Similarity and Truth Estimation for Propagated Segmentations and its application to hippocampal segmentation and brain parcelation. <i>Med Image Anal</i> . 2013;17(6):671-684. doi:10.1016/j.media.2013.02.006
413 414 415	16.	Sudre CH, Cardoso MJ, Bouvy WH, Biessels GJ, Barnes J, Ourselin S. Bayesian Model Selection for Pathological Neuroimaging Data Applied to White Matter Lesion Segmentation. <i>IEEE Trans Med Imaging</i> . 2015;34(10):2079-2102. doi:10.1109/TMI.2015.2419072
416 417 418	17.	Lane CA, Barnes J, Nicholas JM, et al. Associations Between Vascular Risk Across Adulthood and Brain Pathology in Late Life: Evidence From a British Birth Cohort. <i>JAMA Neurol</i> . 2020;77(2):175-183. doi:10.1001/jamaneurol.2019.3774
419 420 421 422	18.	Lane CA, Barnes J, Nicholas JM, et al. Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study. <i>Lancet Neurol</i> . 2019;18(10):942-952. doi:10.1016/S1474-4422(19)30228-5
423 424 425	19.	Bann D, Holly JMP, Lashen H, et al. Changes in insulin-like growth factor-I and -II associated with fat but not lean mass in early old age. <i>Obes Silver Spring Md</i> . 2015;23(3):692-698. doi:10.1002/oby.21002
426 427 428	20.	Clemmons DR. Consensus Statement on the Standardization and Evaluation of Growth Hormone and Insulin-like Growth Factor Assays. <i>Clin Chem</i> . 2011;57(4):555-559. doi:10.1373/clinchem.2010.150631
429 430 431	21.	Kucera R, Topolcan O, Pecen L, et al. Reference values of IGF1, IGFBP3 and IGF1/IGFBP3 ratio in adult population in the Czech Republic. <i>Clin Chim Acta</i> . 2015;444:271-277. doi:10.1016/j.cca.2015.02.036
432 433	22.	Richards M, Barnett JH, Xu MK, et al. Lifetime affect and midlife cognitive function: prospective birth cohort study. <i>Br J Psychiatry</i> . 2014;204(3):194-199. doi:10.1192/bjp.bp.113.128942
434 435 436	23.	Richards M, Shipley B, Fuhrer R, Wadsworth MEJ. Cognitive ability in childhood and cognitive decline in mid-life: longitudinal birth cohort study. <i>BMJ</i> . 2004;328(7439):552. doi:10.1136/bmj.37972.513819.EE
437 438 439	24.	Hsieh S, Schubert S, Hoon C, Mioshi E, Hodges JR. Validation of the Addenbrooke's Cognitive Examination III in frontotemporal dementia and Alzheimer's disease. <i>Dement Geriatr Cogn</i> <i>Disord</i> . 2013;36(3-4):242-250. doi:10.1159/000351671
440	25.	Kuh D, Hardy R, Richards M, et al. MRC NSHD 2013-2018 Data. 2016. doi:10.5522/NSHD/Q103
441 442 443	26.	Richards M, James S-N, Sizer A, et al. Identifying the lifetime cognitive and socioeconomic antecedents of cognitive state: seven decades of follow-up in a British birth cohort study. <i>BMJ Open</i> . 2019;9(4):e024404. doi:10.1136/bmjopen-2018-024404
		18

444 445 446	27.	Kaklamani VG, Linos A, Kaklamani E, Markaki I, Mantzoros C. Age, Sex, and Smoking Are Predictors of Circulating Insulin-Like Growth Factor 1 and Insulin-Like Growth Factor–Binding Protein 3. <i>J Clin Oncol</i> . 1999;17(3):813-813. doi:10.1200/JCO.1999.17.3.813
447 448 449	28.	Chigogora S, Zaninotto P, Kivimaki M, Steptoe A, Batty GD. Insulin-like growth factor 1 and risk of depression in older people: the English Longitudinal Study of Ageing. <i>Transl Psychiatry</i> . 2016;6(9):e898-e898. doi:10.1038/tp.2016.167
450 451 452	29.	Hardy R, Maddock J, Ghosh AK, Hughes AD, Kuh D. The relationship between pubertal timing and markers of vascular and cardiac structure and function in men and women aged 60–64 years. <i>Sci Rep</i> . 2019;9. doi:10.1038/s41598-019-47164-x
453 454	30.	Goldberg DP, Hillier VF. A scaled version of the General Health Questionnaire. <i>Psychol Med</i> . 1979;9(1):139-145. doi:10.1017/s0033291700021644
455 456 457	31.	James S-N, Davis D, O'Hare C, et al. Lifetime affective problems and later-life cognitive state: Over 50 years of follow-up in a British birth cohort study. <i>J Affect Disord</i> . 2018;241:348-355. doi:10.1016/j.jad.2018.07.078
458 459	32.	Buuren S van, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. <i>J Stat Softw</i> . 2011;45(1):1-67. doi:10.18637/jss.v045.i03
460 461	33.	R Core Team. <i>R: A Language and Environment for Statistical Computing</i> . Vienna, Austria: R Foundation for Statistical Computing; 2018. https://www.R-project.org/.
462 463 464	34.	Davis D, Bendayan R, Muniz Terrera G, Hardy R, Richards M, Kuh D. Decline in Search Speed and Verbal Memory Over 26 Years of Midlife in a British Birth Cohort. <i>Neuroepidemiology</i> . 2017;49(3-4):121-128. doi:10.1159/000481136
465 466 467	35.	Okereke O, Kang JH, Ma J, Hankinson SE, Pollak MN, Grodstein F. Plasma IGF-I levels and cognitive performance in older women. <i>Neurobiol Aging</i> . 2007;28(1):135-142. doi:10.1016/j.neurobiolaging.2005.10.012
468 469 470	36.	Perice L, Barzilai N, Verghese J, et al. Lower circulating insulin-like growth factor-l is associated with better cognition in females with exceptional longevity without compromise to muscle mass and function. <i>Aging.</i> 2016;8(10):2414-2424. doi:10.18632/aging.101063
471 472 473	37.	Tumati S, Burger H, Martens S, van der Schouw YT, Aleman A. Association between Cognition and Serum Insulin-Like Growth Factor-1 in Middle-Aged & Older Men: An 8 Year Follow-Up Study. <i>PloS One</i> . 2016;11(4):e0154450. doi:10.1371/journal.pone.0154450
474 475	38.	Piriz J, Muller A, Trejo JL, Torres-Aleman I. IGF-I and the aging mammalian brain. <i>Exp Gerontol</i> . 2011;46(2-3):96-99. doi:10.1016/j.exger.2010.08.022
476 477 478	39.	Westwood AJ, Beiser A, DeCarli C, et al. Insulin-like growth factor-1 and risk of Alzheimer dementia and brain atrophy. <i>Neurology</i> . 2014;82(18):1613-1619. doi:10.1212/WNL.000000000000382
479 480 481	40.	Saber H, Himali JJ, Beiser AS, et al. Serum Insulin-Like Growth Factor 1 and the risk of Ischemic Stroke: The Framingham Study. <i>Stroke</i> . 2017;48(7):1760-1765. doi:10.1161/STROKEAHA.116.016563

482 483 484	41.	Åberg D, Jood K, Blomstrand C, et al. Serum IGF-I Levels Correlate to Improvement of Functional Outcome after Ischemic Stroke. <i>J Clin Endocrinol Metab</i> . 2011;96(7):E1055-E1064. doi:10.1210/jc.2010-2802	
485 486 487	42.	Tarantini S, Valcarcel-Ares NM, Yabluchanskiy A, et al. Insulin-like growth factor 1 deficiency exacerbates hypertension-induced cerebral microhemorrhages in mice, mimicking the aging phenotype. <i>Aging Cell</i> . 2017;16(3):469-479. doi:10.1111/acel.12583	
488 489	43.	Allard JB, Duan C. IGF-Binding Proteins: Why Do They Exist and Why Are There So Many? <i>Front</i> Endocrinol. 2018;9. doi:10.3389/fendo.2018.00117	
490 491 492	44.	Baxter RC. Insulin-like growth factor binding protein-3 (IGFBP-3): Novel ligands mediate unexpected functions. <i>J Cell Commun Signal</i> . 2013;7(3):179-189. doi:10.1007/s12079-013- 0203-9	
493 494 495	45.	Wennberg AMV, Hagen CE, Machulda MM, et al. The association between peripheral total IGF 1, IGFBP-3, and IGF-1/IGFBP-3 and functional and cognitive outcomes in the Mayo Clinic Study of Aging. <i>Neurobiol Aging</i> . 2018;66:68-74. doi:10.1016/j.neurobiolaging.2017.11.017	
496 497 498	46.	Almeida OP, Hankey GJ, Yeap BB, Paul Chubb SA, Gollege J, Flicker L. Risk of prevalent and incident dementia associated with insulin-like growth factor and insulin-like growth factor- binding protein 3. <i>Mol Psychiatry</i> . 2018;23(8):1825-1829. doi:10.1038/mp.2017.152	
499 500 501	47.	Dai H, Goto Y, Itoh M. Insulin-Like Growth Factor Binding Protein-3 Deficiency Leads to Behavior Impairment with Monoaminergic and Synaptic Dysfunction. <i>Am J Pathol.</i> 2017;187(2):390-400. doi:10.1016/j.ajpath.2016.10.011	
502 503 504	48.	Johnsen SP, Hundborg HH, Sørensen HT, et al. Insulin-Like Growth Factor (IGF) I, -II, and IGF Binding Protein-3 and Risk of Ischemic Stroke. <i>J Clin Endocrinol Metab</i> . 2005;90(11):5937-5941 doi:10.1210/jc.2004-2088	
505 506 507 508	49.	Armbrust M, Worthmann H, Dengler R, et al. Circulating Insulin-like Growth Factor-1 and Insulin-like Growth Factor Binding Protein-3 predict Three-months Outcome after Ischemic Stroke. <i>Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc</i> . 2017;125(7):485-491. doi:10.1055/s-0043-103965	
509 510 511	50.	Chang K-H, Chan-Ling T, McFarland EL, et al. IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development. <i>Proc Natl Acad</i> <i>Sci</i> . 2007;104(25):10595-10600. doi:10.1073/pnas.0702072104	
512 513	51.	Reik W, Constancia M, Dean W, et al. Igf2 imprinting in development and disease. Int J Dev Biol. 2000;44(1):145-150.	
514 515 516	52.	Kalmijn S, Janssen J a. MJL, Pols H a. P, Lamberts SWJ, Breteler MMB. A Prospective Study on Circulating Insulin-Like Growth Factor I (IGF-I), IGF-Binding Proteins, and Cognitive Function in the Elderly. <i>J Clin Endocrinol Metab</i> . 2000;85(12):4551-4555. doi:10.1210/jcem.85.12.7033	
517 518 519	53.	Yamamoto H, Sohmiya M, Oka N, Kato Y. Effects of aging and sex on plasma insulin-like growth factor I (IGF-I) levels in normal adults. <i>Acta Endocrinol (Copenh)</i> . 1991;124(5):497-500. doi:10.1530/acta.0.1240497	1
520 521	54.	Joseph D'Ercole A, Ye P. Expanding the Mind: Insulin-Like Growth Factor I and Brain Development. <i>Endocrinology</i> . 2008;149(12):5958-5962. doi:10.1210/en.2008-0920	
		2	0

- 52255.Al-Delaimy WK, von Muhlen D, Barrett-Connor E. IGF-1 and IGFBP-1 and Cognitive Function in523Older Men and Women. J Am Geriatr Soc. 2009;57(8):1441-1446. doi:10.1111/j.1532-
- 524 5415.2009.02343.x

531 Table 1

		NSHD (n=1762)		Insight 46 (n=378)	
	53 Years	60-64 Years	69 Years	69 – 71 years	P-value ¹
Exposures					
IGF-I levels (nmol/L)	26.22 (9.00)	23.00 (7.71)			< 0.001
IGFBP-3 levels (nmol/L)	173.22 (39.31)	120.11 (30.16)			< 0.001
IGF-I/IGFBP-3 molar ratio	0.16 (0.06)	0.20 (0.06)			< 0.001
IGF-II levels (nmol/L)	99.82 (32.36)	87.86 (38.60)			< 0.001
Cognitive tests					
Addenbrooke's Cognitive Examination			91.52		
(ACE-III) score Visual Letter Search (VLS) score	283.52 (73.34)	268.25	(6.01) 263.56 (74.22)		< 0.001
Word Learning Test (WLT) score	(73.34) 24.87 (6.12)	(70.54) 24.68 (6.06)	(74.32) 22.38 (6.13)		< 0.001
Insight 46 MRI measures					
Age at scan				70.67 (0.67)	
Hippocampal volume (ml)				3.13 (0.33)	
Total intracranial volume (ml)				1432.86 (127.58)	
White matter hyperintensity volume $^{2}\left(m\right)$				3.08 (5.19)	
Whole brain volume (ml)				(95.34)	
Model covariates					
Early life cognition	0.14 (0.69)				
Affective Symptoms Case Status					
Non-case	1313 (81%)	1247 (83%)	1505 (86%)		
Case	316 (19%)	264 (17%)	251 (14%)		
Educational attainment					
No qualifications/vocational only	637 (36%)				
O-Level/A-Level or equivalent	835 (48%)				
Higher	272 (16%)				
Smoking status	·				
Current smoker	315 (19%)	148 (10%)	525 (9%)		
Ex smoker	842	875	1061		
	(51%)	(58%)	(61%)		
Never smoker	507 (30%)	489 (32%)	525 (30%)		


¹P-values were calculated using a one-way ANOVA for continuous variables. ²Median and interquartile range

533 presented for non-normally distributed variables

535 Figures


536 Figure 1:

537



538

Figure 2 :



546 Figure 3



Age at cognitive testing 60-64 Years 69 Years 280 270 VLS 260 250 240 Score on cognitive test (95% CI) .61 .62 .63 .61 Tertile 1 WLT 2 (Ref.) 3 Fully adjusted Fully Sex Sex adjusted adjusted adjusted IGF-II IGF-II (60-64 Years) 92 (53 Years) 90 ACE-III 88 86 Fully adjusted Fully adjusted Sex adjusted Sex adjusted IGF-II IGF-II (53 Years) (60-64 Years)

548


549

550

552 Figure 4:

553

554



556

557 Legends for Figures and Tables

- 558 Table 1:
- 559 Table presents variable information for the sample (n = 1762 (NSHD) and n= 378 (INSIGHT)) prior to
- 560 imputation.

561

- 562 Figure 1:
- 563 NSHD study flow diagram. Abbreviations: Insulin-Growth Factor-I (IGF-I), Insulin Growth Factor-II
- 564 (IGF-II), Insulin-Growth Factor Binding Protein-3 (IGFBP-3), Addenbrookes Cognitive Exam-III (ACE-
- 565 III), Word Learning Test (WLT), VLS (Visual Letter Search) test, Whole Brain Volume (WBV), White
- 566 Matter Hyperintensity volume (WMHV), Mean Hippocampal Volume (MHV).

567 Figure 2:

- 568 Beta coefficient and 95% confidence interval for the effect of IGF-I, IGFBP-3 and IGF-I/IGFBP-3 at
- ages 53y and 60-64y on visual memory (WLT) and processing speed (VLS) at ages 60-64y and 69y and
- 570 cognitive state (ACE-III) at age 69y. Models were adjusted for sex (base model), sex, early life
- 571 cognition and lifetime education (+ childhood cognition and education model), sex, early life
- 572 cognition, lifetime education and smoking (+ lifestyle factors) and sex, early life cognition, lifetime
- 573 education, smoking and depressive symptoms (+depressive symptoms). Abbreviations: Insulin-
- 574 Growth Factor-I (IGF-I), Insulin-Growth Factor Binding Protein-3 (IGFBP-3), Addenbrookes Cognitive
- 575 Exam-III (ACE-III), Word Learning Test (WLT), VLS (Visual Letter Search) test


577 Figure 3:

578	Predicted scores and 95% confidence intervals for the effect of IGF-II tertiles at ages 53y and 60-64y
579	on ACE-III, WLT and VLS predicted score, in sex-adjusted and fully adjusted models (sex, early life
580	cognition, lifetime education, smoking and depressive symptoms). Tertile 2 presents the reference
581	category used in the regression. Abbreviations: Insulin-Growth Factor-I (IGF-I), Insulin-Growth Factor
582	Binding Protein-3 (IGFBP-3), Addenbrooke's Cognitive Exam-III (ACE-III), Word Learning Test (WLT),
583	VLS (Visual Letter Search) test


584

585 Figure 4:


- 586 Beta coefficient and 95% confidence interval for the effect of IGF-I, IGFBP-3 and IGF-I/IGFBP-3 at
- ages 53y and 60-64y on Total Brain Volume (TBV), White Matter Hyperintensity volume (WMHV) and
- 588 Mean Hippocampal Volume (MHV) at age 69y in the Insight 46 sub-study. Models were adjusted for
- 589 sex and age at scan (base model), sex, early life cognition and lifetime education (+ childhood
- 590 cognition and education model), sex, age at scan, early life cognition, lifetime education and smoking
- 591 (+ lifestyle factors) and sex, age at scan, early life cognition, lifetime education, smoking and
- 592 depressive symptoms (+depressive symptoms).




Age at cognitive testing



Age at cognitive testing





IGE-I/IGERP-3

 $\sum_{i=1}^{n} \sum_{i=1}^{n} \sum_{i$